Back to search results

Vibrotactile Coordinated Reset for Parkinson's Disease

This study is exploring a new approach called Vibrotactile Coordinated Reset (vCR) stimulation for people with Parkinson's disease. This treatment uses a device called the Stanford Glove, which delivers gentle vibrations to your fingertips. The goal is to see if vCR can help improve Parkinson's symptoms, potentially offering an alternative to common treatments like Levodopa or deep brain stimulation. You might be able to join if you are 18 or older, have been diagnosed with Parkinson's, speak English, and have a certain score on a Parkinson's motor test (UPDRS III of at least 30). The study will measure success by looking at changes in your Parkinson's symptoms after 6 months. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 34 participants. The study will test the effects of vibrotactile coordinated reset stimulation.
What's involved
You would be followed for 14 months, with your Parkinson's symptoms assessed at the beginning and at 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 14 months after the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06028477

Vibrotactile Coordinated Reset in Parkinson's Disease - Proof of Concept Study

Not Yet Recruiting
NAAges 18–92InterventionalTreatment
Stanford University
~34 participants
Updated 2024-08-19 on ClinicalTrials.gov
What's tested:Stanford Glove

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in MDS-Unified Parkinson's Disease Rating Scale Part III Scale Score
Measured over Baseline and month 6

Conditions

Parkinson Disease

Explore related trials

Parkinson Disease

NCT06028477

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Stanford University

    Stanford, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Vivek P Buch, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Jessica Yankulova
[email protected]
650-474-9547
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed with idiopathic Parkinson's Disease
Fluent in English
Off-state UPDRS III motor score at least 30, as assessed within the past 6 months before study consent or at Screening Visit.
Demonstrates understanding of the study requirements and is able and willing to sign the informed consent form and complete study procedures.

Exclusion

Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. Any other trial participation should be approved by the Principal Investigators.
Pregnancy, breast-feeding or wanting to become pregnant
Physical limitations unrelated to PD that would affect motor ratings
Has implantation of a medical device
Sensory abnormalities of the fingertips

What this trial measures

  • Change in MDS-Unified Parkinson's Disease Rating Scale Part III Scale ScoreBaseline and month 6

    Mean change in the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score. Minimum score - 0 indicates normal functioning Maximum score - 132 indicated severe impairment Lower scores indicate greater functionality and higher scores indicate severe impairment in functionality.